A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

S-1 plus weekly split-dose cisplatin demonstrated promising results in previous phase I and II studies for advanced gastric cancer (AGC) patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Gastric Cancer

Title: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

ISSN (Electronic): 1436-3305

ISSN (Print): 1436-3291

Publication date (Electronic): Apr 2014

Volume: 17

Issue: 2

Affiliations

[1 ] Division of Gastroenterology, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305-0006, Japan, tmoriwak@gmail.com.

Article

DOI: 10.1007/s10120-013-0284-4

PubMed ID: 23852397

SO-VID: 42bd0581-871e-4db4-9ef6-6104af2b2e48

History

Data availability:

Comments

Comment on this article

scite_

Cited by 1

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
Authors: Bo Zhu, Jun-Rong Wu, Xiao-Ping Zhou

See all cited by